Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Accounts Payables (2023 - 2026)

MBX Biosciences has reported Accounts Payables over the past 4 years, most recently at $7.0 million for Q1 2026.

  • Quarterly results put Accounts Payables at $7.0 million for Q1 2026, up 64.29% from a year ago — trailing twelve months through Mar 2026 was $7.0 million (up 64.29% YoY), and the annual figure for FY2025 was $3.0 million, down 44.2%.
  • Accounts Payables reached $7.0 million in Q1 2026 per MBX's latest filing, up from $3.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.0 million in Q1 2026 and bottomed at $1.4 million in Q4 2023.
  • Median Accounts Payables over the past 4 years was $4.6 million (2024), compared with a mean of $4.4 million.
  • The largest annual shift saw Accounts Payables surged 283.54% in 2024 before it tumbled 44.2% in 2025.
  • Over 4 years, Accounts Payables stood at $1.4 million in 2023, then soared by 283.54% to $5.3 million in 2024, then plummeted by 44.2% to $3.0 million in 2025, then soared by 134.26% to $7.0 million in 2026.
  • Business Quant data shows Accounts Payables for MBX at $7.0 million in Q1 2026, $3.0 million in Q4 2025, and $3.8 million in Q3 2025.